Emerging biomarkers in Gaucher disease

Area of Science:

• Biochemistry
• Genetics
• Lysosomal Storage Disorders

Background:

• Gaucher disease (GD) is a rare lysosomal disorder caused by glucocerebrosidase (GCase) deficiency, leading to glycosphingolipid accumulation.
• GD presents in three subtypes (GD1, GD2, GD3) with varying severity and manifestations, including organomegaly, anemia, and neurological symptoms.
• Current biomarkers for GD are nonspecific, hindering accurate subtype differentiation, disease monitoring, and therapeutic guidance.

Purpose of the Study:

• To provide a comprehensive review of emerging biomarkers for Gaucher disease.
• To highlight the potential of novel biomarkers in improving GD diagnosis and monitoring.
• To discuss how new biomarkers can aid in identifying therapeutic targets and enhancing patient quality of life.

Main Methods:

• Literature review of emerging biomarkers for Gaucher disease.
• Analysis of current diagnostic and monitoring tools for GD.
• Synthesis of information on biomarker potential for GD management.

Main Results:

• Existing GD biomarkers lack specificity for subtype classification and disease progression tracking.
• Emerging biomarkers show promise for more accurate GD diagnosis and monitoring.
• Novel biomarkers may facilitate personalized treatment strategies and the discovery of new therapeutic avenues.

Conclusions:

• There is a critical need for improved biomarkers in Gaucher disease management.
• Emerging biomarkers offer significant potential to enhance diagnostic accuracy and therapeutic monitoring.
• Further research into novel biomarkers is essential for advancing GD patient care and outcomes.